Xinhua News Agency, Beijing, November 19 (Reporters Dong Ruifeng, Xu Penghang) The reporter learned from the State Council’s Joint Prevention and Control Mechanism Scientific Research Team that China’s self-developed new crown drugs have completed phase III clinical trials and are applying for conditional listing
State Council From the hundreds of antibodies isolated from the blood of convalescent patients, 2 strains of antibodies with high activity and strong complementarity were screened-the new coronavirus antibody combination drug BRII developed by Tsinghua University, Shenzhen Third People's Hospital and Tengsheng Biopharmaceutical team -196/BRII-198, has recently completed the foreign phase III clinical trials, and has been urgently called by the relevant departments to provide clinical treatment for more than 800 cases of infection in China
According to Zhang Linqi, a professor at the School of Medicine of Tsinghua University, foreign phase III clinical trial data show that the antibody combination drug can reduce severe illness and mortality by 78%, and it still maintains activity against the new coronavirus variant
By the Chinese Kexue Yuan Institute of Microbiology and Shanghai Jun real biological joint development of neutralizing antibodies JS016, has also been completed Ⅱ international multi-center clinical trial in November, the current data show achieved a positive effect
Academy of Sciences "Our partnership with international pharmaceutical companies, as of now JS016 has received emergency use authorization in 15 countries around the world, dispensing medications more than 500,000 worldwide
Zhong ASTRI ASTRI According to another report, the new generation of androgen receptor antagonist prokruamide of Suzhou Kaifeng Pharmaceutical and Azivudine of Henan Normal University are carrying out phase III clinical trials at home and abroad, and the neutralizing antibody BGB of Peking University and Beijing Danxu -DXP-604 as well as in Keyuan Shanghai Institute of drugs FB2001, VV116 also in the development process
Zhong ASTRI ASTRI According to the person in charge of the State Council’s Joint Prevention and Control Mechanism Scientific Research Group, the current research and development of new crown drugs is mainly carried out on three technical routes: blocking viruses from entering cells, inhibiting virus replication, and regulating the human immune system.
State Council The State Council’s Joint Prevention and Control Mechanism Scientific Research Team , which is composed of the Ministry of Science and Technology, the National Health Commission, the Ministry of Industry and Information Technology, the National Development and Reform Commission, the State Food and Drug Administration, and the State Administration of Traditional Chinese Medicine.
State Council
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
